GlassScriptPhysician profile
Sarah E Hirschman
NPI 1629491113
$13,002.49
in general payments reported to CMS, 2019-2025
33 companies · $3,085 in 2025
The $3,085 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,349 · 2022: $2,314 · 2023: $3,137 · 2024: $3,118 · 2025: $3,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,647 · Education: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,646.57 |
| Education | $693.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,825.13 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,501.90 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $1,457.46 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,077.41 | 2021-2025 | |
| Lilly USA, LLC | $764.43 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $713.84 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $676.74 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $577.64 | 2021-2025 | |
| Ucb, INC. | $564.47 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $497.73 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $427.69 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $394.14 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $368.23 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $338.94 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $290.88 | 2023-2024 | Zoryve |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $248.66 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $185.31 | 2023-2025 | |
| Vyne Pharmaceuticals INC. | $141.43 | 2021 | |
| Organogenesis INC. | $135.74 | 2024-2025 | Simplimax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.12 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.14 | 2021-2025 | Cabtreo, Arazlo, Jublia |
| Organon LLC | $121.19 | 2023-2025 | Vtama, Hadlima |
| Janssen Scientific Affairs, LLC | $81.85 | 2022 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Allergan, INC. | $64.64 | 2022 | |
| Verrica Pharmaceuticals INC. | $53.83 | 2023-2024 | Ycanth |
| Smith+Nephew, INC. | $45.96 | 2023 | Grafix Pl, Collagenase Santyl |
| Genentech USA, INC. | $24.44 | 2022 | |
| Almirall LLC | $22.59 | 2022 | |
| Mimedx Group, INC. | $22.31 | 2025 | |
| Botanix Sb INC | $20.00 | 2025 | Sofdra |
| Journey Medical Corporation | $15.65 | 2022 | |
| Biofrontera INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hirschman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.